Literature DB >> 20147973

Lck is a key target of imatinib and dasatinib in T-cell activation.

K C Lee, I Ouwehand, A L Giannini, N S Thomas, N J Dibb, M J Bijlmakers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20147973     DOI： 10.1038/leu.2010.11

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  38 in total

1.  Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

Authors:  Hugues de Lavallade; Ahmad Khoder; Melanie Hart; Anushruti Sarvaria; Takuya Sekine; Abdullah Alsuliman; Stephan Mielke; Alexandra Bazeos; Kate Stringaris; Sara Ali; Dragana Milojkovic; Letizia Foroni; Aristeidis Chaidos; Nichola Cooper; Ian Gabriel; Jane Apperley; Sarah Belsey; Robert J Flanagan; John Goldman; Elizabeth J Shpall; Peter Kelleher; David Marin; Katayoun Rezvani
Journal:  Blood       Date:  2013-05-29       Impact factor: 22.113

2.  Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.

Authors:  Angeles Alvarez Secord; Deanna Teoh; Jingquan Jia; Andrew B Nixon; Lisa Grace; David J Adams; Susan K Murphy
Journal:  Int J Gynecol Cancer       Date:  2014-02       Impact factor: 3.437

3.  Pharmacologic control of CAR-T cell function using dasatinib.

Authors:  Evan W Weber; Rachel C Lynn; Elena Sotillo; John Lattin; Peng Xu; Crystal L Mackall
Journal:  Blood Adv       Date:  2019-03-12

4.  Role of increased guanosine triphosphate cyclohydrolase-1 expression and tetrahydrobiopterin levels upon T cell activation.

Authors:  Wei Chen; Li Li; Torben Brod; Omar Saeed; Salim Thabet; Thomas Jansen; Sergey Dikalov; Cornelia Weyand; Jorg Goronzy; David G Harrison
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

5.  Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.

Authors:  Sandra P D'Angelo; Alexander N Shoushtari; Mary Louise Keohan; Mark A Dickson; Mrinal M Gounder; Ping Chi; Jennifer K Loo; Leigh Gaffney; Lee Schneider; Zarine Patel; Joseph Patrick Erinjeri; Mark J Bluth; Ana Sjoberg; Howard Streicher; Naoko Takebe; Li-Xuan Qin; Cristina Antonescu; Ronald P DeMatteo; Richard D Carvajal; William D Tap
Journal:  Clin Cancer Res       Date:  2016-12-22       Impact factor: 12.531

6.  Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.

Authors:  Matthias Wölfl; Stefanie Schwinn; Young-Eun Yoo; Marie L Reß; Matthias Braun; Martin Chopra; Susanne C Schreiber; Victor I Ayala; Claes Ohlen; Matthias Eyrich; Andreas Beilhack; Paul G Schlegel
Journal:  Blood       Date:  2013-07-08       Impact factor: 22.113

7.  NKG2D gene polymorphisms are associated with disease control of chronic myeloid leukemia by dasatinib.

Authors:  Ryujiro Hara; Makoto Onizuka; Erika Matsusita; Eri Kikkawa; Yoshihiko Nakamura; Hiromichi Matsushita; Daisuke Ohgiya; Hiromichi Murayama; Shinichiro Machida; Ken Ohmachi; Yukari Shirasugi; Yoshiaki Ogawa; Hiroshi Kawada; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2017-08-09       Impact factor: 2.490

8.  E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.

Authors:  Jesús Duque-Afonso; Chiou-Hong Lin; Kyuho Han; Michael C Wei; Jue Feng; Jason H Kurzer; Corina Schneidawind; Stephen Hon-Kit Wong; Michael C Bassik; Michael L Cleary
Journal:  Cancer Res       Date:  2016-10-07       Impact factor: 12.701

9.  Principal component analysis uncovers cytomegalovirus-associated NK cell activation in Ph+ leukemia patients treated with dasatinib.

Authors:  K Ishiyama; T Kitawaki; N Sugimoto; T Sozu; N Anzai; M Okada; M Nohgawa; K Hatanaka; N Arima; T Ishikawa; S Tabata; T Onaka; S Oka; Y Nakabo; R Amakawa; M Matsui; T Moriguchi; A Takaori-Kondo; N Kadowaki
Journal:  Leukemia       Date:  2016-06-14       Impact factor: 11.528

Review 10.  Immunological off-target effects of imatinib.

Authors:  Laurence Zitvogel; Sylvie Rusakiewicz; Bertrand Routy; Maha Ayyoub; Guido Kroemer
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.